Inactive Instrument

MASR PHAR

MPH

PLMSTPH00016

Master Pharm SA Reports Earnings Results for the First Quarter Ended March 31, 2022

May 13, 2022 at 05:02 pm IST

Master Pharm SA reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was PLN 18.55 million compared to PLN 22.36 million a year ago. Net income was PLN 0.724 million compared to PLN 1.29 million a year ago.

Latest news about MASR PHAR

Farmaceutici Procemsa SPA signed an agreement to acquire an unknown majority stake in Master Pharm SA.	16/23/16	CI
Master Pharm SA's Equity Buyback announced on June 24, 2020, has expired.	24/23/24	CI
Master Pharm SA Reports Earnings Results for the Half Year Ended June 30, 2022	21/22/21	CI
Master Pharm SA announces an Equity Buyback for 2,600,000 shares, for PLN 15.86 million.	14/22/14	CI
Master Pharm SA authorizes a Buyback Plan.	14/22/14	CI
Master Pharm SA Reports Earnings Results for the First Quarter Ended March 31, 2022	13/22/13	CI
Master Pharm SA Reports Earnings Results for the Full Year Ended December 31, 2021	27/22/27	CI
Master Pharm SA Reports Earnings Results for the Nine Months Ended September 30, 2021	19/21/19	CI
Master Pharm SA's Equity Buyback announced on October 4, 2021, has expired.	13/21/13	CI
Master Pharm SA announces an Equity Buyback for 1,000,000 shares, for PLN 4.5 million.	04/21/04	CI
Master Pharm SA authorizes a Buyback Plan.	04/21/04	CI
Master Pharm Sa Reports Earnings Results for the Half Year Ended June 30, 2021	30/21/30	CI
Tranche Update on Master Pharm SA's Equity Buyback Plan announced on June 24, 2020.	17/21/17	CI
Master Pharm SA Reports Earnings Results for the First Quarter Ended March 31, 2021	17/21/17	CI
Tranche Update on Master Pharm SA's Equity Buyback Plan announced on June 24, 2020.	15/21/15	CI
Master Pharm Sa Reports Earnings Results for the Full Year Ended December 31, 2020	15/21/15	CI
Tranche Update on Master Pharm SA's Equity Buyback Plan announced on June 24, 2020.	19/20/19	CI
Master Pharm Sa Announces Earnings Results for the Nine Months Ended September 30, 2020	19/20/19	CI
Tranche Update on Master Pharm SA's Equity Buyback Plan announced on June 24, 2020.	24/20/24	CI
Master Pharm Sa Reports Earnings Results for the Half Year Ended June 30, 2020	24/20/24	CI
Master Pharm SA announces an Equity Buyback for 4,300,000 shares, for PLN 18.2 million.	24/20/24	CI
An unknown natural person acquired AvetPharma Sp. z o.o. from Master Pharm SA for PLN 1000.	24/19/24	CI
Master Pharm Mulls Potential Acquisitions	09/18/09	CI
Master Pharm SA Withdraws Talks To Acquire Business Of Company Operating In Pharma	21/17/21	CI
Certain Series A Common Shares of Master Pharm SA are subject to a Lock-Up Agreement Ending on 27-APR-2017.	27/17/27	CI

Chart MASR PHAR

Duration

Period

More charts

Company Profile

Master Pharm SA is a Poland-based company primarily engaged in the manufacture of wellbeing products. The Company specializes in designing and producing diet supplements, food for special nutritional purposes, dietary products, cosmetics, medical devices, as well as other consumables for third parties. Its activities are divided into four operating areas: Contract manufacturing, including designing technology and ingredients of products, manufacturing, packaging, labeling, and marking, among others; Preparation of product documentation, providing product specification, certificate of ingredients and technical etiquette; Import-export, trading with raw materials and food supplements, and Medical Devices, offering medical device design, tests, documentation, and registration. The Company cooperates with Adamed, Bioton, Synoptis, Polpharma, Pharmena, and Salvum, among others. The main shareholder of the Company is Max Welt Holdings Ltd.

Sector

Food Processing

More about the company

Sector Special Foods & Wellbeing Products

	1st Jan change	Capi.
ZHEJIANG NHU COMPANY LTD.	+11.85%	8.05B
BELLRING BRANDS, INC.	+4.94%	7.59B
CSPC INNOVATION PHARMACEUTICAL CO., LTD.	+2.63%	6.07B
THE SIMPLY GOOD FOODS COMPANY	-2.80%	3.85B
BYHEALTH CO., LTD	-11.22%	3.55B
XIAMEN KINGDOMWAY GROUP COMPANY	-7.04%	1.28B
HERBALIFE LTD.	-32.50%	1.03B
SIRIO PHARMA CO., LTD.	+12.52%	971M
USANA HEALTH SCIENCES, INC.	-11.19%	907M

Special Foods & Wellbeing Products